CytomX reports Q4 rev $19.7M, cash $305.2M; CX-2029 18.8% ORR, CX-904 IND allowed

CytomX Therapeutics, Inc.

Cash and equivalents $305.2M at Dec 31, 2021 vs $316.1M at Dec 31, 2020.
Q4 2021 revenue $19.7M (up from $16.4M in Q4 2020); FY 2021 revenue $69.6M (down from $100.4M).
CX-2029 Phase 2 in sqNSCLC: 18.8% objective response rate, 87.5% disease control rate; safety consistent.
CX-904 (EGFRxCD3 TCB) IND allowed; Phase 1 in advanced solid tumors to start H1 2022.
Praluzatamab ravtansine Phase 2 in breast cancer: initial data for Arms A & B expected H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.